###begin article-title 0
###xml 15 42 15 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum dhfr </italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 15 36 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 191 199 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Both chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) are failing drugs in much of sub-Saharan Africa. Previous findings suggest an association between resistance to CQ and to SP in vivo, in vitro, and on the molecular level.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 113 159 113 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum dihydrofolate reductase </italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr</italic>
###xml 174 209 174 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">chloroquine resistance transporter </italic>
###xml 210 213 210 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 16 24 <span type="species:ncbi:9606">children</span>
###xml 113 134 <span type="species:ncbi:5833">Plasmodium falciparum</span>
In 126 Ghanaian children with uncomplicated malaria, associations between mutations conferring resistance in the Plasmodium falciparum dihydrofolate reductase (dhfr; SP) and chloroquine resistance transporter (crt; CQ) genes, concentrations of residual antimalarial drugs, and gametocyte carriage were examined.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 305 310 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 499 503 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
Mutant dhfr alleles and the CQ-resistance allele crt T76 were strongly associated with each other. Isolates exhibiting the dhfr triple mutation seven times more likely also contained crt T76 parasites as compared to isolates without the dhfr triple variant (P = 0.0001). Moreover, both, isolates with the dhfr triple mutation (adjusted OR, 3.2 (95%CI, 1.0-10.4)) and with crt T76 (adjusted OR, 14.5 (1.4-150.8)) were associated with an increased likelihood of pre-treatment gametocytaemia. However, crt T76 did not correlate with gametocytaemia following SP treatment and no selection of crt T76 in SP treatment failure isolates was observed.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
These results confirm an association between CQ and SP resistance markers in isolates from northern Ghana. This could indicate accelerated development of resistance to SP if CQ resistance is already present, or vice versa. Considering the enhanced transmission potential as reflected by the increased proportion of isolates containing gametocytes when resistant parasites are present, co-resistance can be expected to spread in this area. However, the underlying mechanism leading to this constellation remains obscure.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 181 203 181 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 181 202 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) are the most frequently used antimalarial drugs in sub-Saharan Africa. With the spread and intensification of drug resistance of Plasmodium falciparum more effective combinatory drug regimes are now introduced in many African countries [1]. However, CQ and SP are cheap and widely available and will most likely be in use for some more years, particularly in home treatment [2-4].
###end p 11
###begin p 12
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 600 610 600 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vice versa</italic>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 646 655 646 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 623 629 <span type="species:ncbi:10090">murine</span>
In several East African countries where SP was introduced in response to intense CQ-resistance, the drug has gradually lost efficacy although the pace of this development is subject to controversy [5,6]. Previously, the core mutations linked with resistance to CQ and SP were found to be associated with each other in isolates from southern Ghana [7]. Although CQ and SP are structurally unrelated and the mutations conferring resistance are located on separate chromosomes [8-10], this finding suggests that parasites resistant to CQ may acquire resistance to SP more easily than sensitive ones, or vice versa. Studies in murine models [11] and in vitro [12,13] support this hypothesis. If this was true, the spread of CQ resistance could pave the way for an accelerated development of SP resistance, and thus, bear substantial importance to the health systems of affected regions. In addition, transmission potential may be increased in both SP and CQ resistant parasites [14,15].
###end p 12
###begin p 13
###xml 27 65 27 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum dihydrofolate reductase </italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr</italic>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 307 361 307 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum chloroquine resistance transporter gene </italic>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 27 40 <span type="species:ncbi:5833">P. falciparum</span>
###xml 307 320 <span type="species:ncbi:5833">P. falciparum</span>
###xml 423 431 <span type="species:ncbi:9606">children</span>
Recently, mutations in the P. falciparum dihydrofolate reductase (dhfr) gene in northern Ghana were observed not only to be predictive for SP treatment failure but also to be associated with increased pre-treatment gametocyte carriage [16]. Here, associations between dhfr alleles, the core mutation in the P. falciparum chloroquine resistance transporter gene (crt T76), residual antimalarials, and gametocyte carriage in children with uncomplicated malaria were re-examined.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 232 259 232 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dihydropteroate synthetase </italic>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps</italic>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 0 13 <span type="species:ncbi:5833">P. falciparum</span>
###xml 43 51 <span type="species:ncbi:9606">children</span>
###xml 354 362 <span type="species:ncbi:9606">children</span>
P. falciparum isolates were collected from children with uncomplicated malaria participating in a treatment trial in Tamale, Northern Region, Ghana, at the end of the rainy season 2002. The results of this trial and on the dhfr and dihydropteroate synthetase gene (dhps) patterns are described elsewhere [16,17]. In the present report, data from all 126 children with complete follow-up after SP treatment for whom dhfr and dhps were genotyped are analysed. The study protocol was approved by the Ethics Committee, Ministry of Health, Northern Region, and by the Health Research Unit, Ministry of Health, Accra, and parents' informed consent was obtained.
###end p 15
###begin p 16
###xml 59 73 59 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 116 118 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 119 121 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 208 210 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 232 234 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 386 388 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 389 391 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 14 22 <span type="species:ncbi:9606">children</span>
###xml 59 72 <span type="species:ncbi:5833">P. falciparum</span>
Patients were children aged 6-59 months with uncomplicated P. falciparum monoinfection (>/= 2,000 </= 200,000/muL) [18,19]. None had severe malnutrition, a febrile disease other than malaria, "danger signs" [18], or severe malaria [20]. Treatment consisted of a single dose of SP (25/1.25 mg/kg, Fansidar, Roche, Switzerland), and success was monitored according to current guidelines [17,19].
###end p 16
###begin p 17
###xml 419 421 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 324 332 <span type="species:ncbi:9606">children</span>
Venous blood was collected into EDTA. Asexual parasites and gametocytes were counted per >/= 200 and 500 white blood cells, respectively, on Giemsa-stained thick blood films, and densities were calculated based on a putative mean WBC count of 8,000/muL. Gametocyte counts one week following treatment were available for 104 children. Pre-treatment levels of CQ and pyrimethamine in blood were measured by ELISA assays [21] with limits of detection of 10 ng/mL and 25 ng/mL, respectively.
###end p 17
###begin p 18
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum dhfr</italic>
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr</italic>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps</italic>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 0 13 <span type="species:ncbi:5833">P. falciparum</span>
P. falciparum dhfr, dhps, and crt alleles were assessed by restriction fragment length polymorphisms (RFLP) of amplicons generated by nested PCR assays applying hot start procedures (HotStart Taq, Qiagen, Germany). Primers and conditions are described elsewhere [22,23] as are restriction enzymes and RFLP conditions to characterize the codons dhfr, 16, 51, 59, 108, 164; dhps, 436, 437, 540, 581, 613; and crt, 76. Laboratory strains were used as controls for PCR and RFLP assays. Electrophoresis was perfomed on 3% GTG agarose (FMC Bioproducts, USA) gels.
###end p 18
###begin p 19
###xml 32 33 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Frequencies were compared by chi2-test or Fisher's exact test, and continuous variables by Student's t-test, Mann-Whitney U-test, or Kruskal-Wallis test as applicable. Logistic regression models were used to adjust for potential confounders of the presence of resistance mutations and to identify risk factors for gametocytaemia.
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
###xml 25 30 <span type="species:ncbi:9606">girls</span>
###xml 38 42 <span type="species:ncbi:9606">boys</span>
###xml 278 286 <span type="species:ncbi:9606">children</span>
###xml 445 453 <span type="species:ncbi:9606">children</span>
The median age of the 68 girls and 58 boys was 28.5 months (range, 6-59). Median axillary temperature and geometric mean parasite density were 38.8degreesC (range, 37.5-41.0) and 36,358/muL (range, 2,068-175,333/muL), respectively. Gametocytes were found in 19% (24/126) of the children at a geometric mean density of 50/muL (16-1,120/muL). CQ in blood was observed in 66% (83/126; median, 32 ng/mL, range, 10-718) but pyrimethamine in only two children (78 & 326 ng/mL).
###end p 21
###begin p 22
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 294 299 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crt </italic>
The dhfr alleles Thr-108, Val-16 and Leu-164 were not detected. Classifying mixed alleles as mutant, dhfr Ile-51 occurred in 56% (70/126), Arg-59 in 65% (82/126), and Asn-108 in 72% (91/126). Triple dhfr mutations (Ile-51/Arg-59/Asn-108) were seen in 47% (59/126), and quadruple (triple dhfr + dhps Gly-437) and quintuple (triple dhfr + dhps Gly-437/Glu-540) variants in 44% (55/126), and 0.8% (1/126), respectively. Crt T76 occurred in 80% (101/126) of the isolates.
###end p 22
###begin p 23
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps</italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhfr </italic>
###xml 209 211 209 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 259 261 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 296 301 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 334 336 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 642 646 642 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 720 721 718 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 721 727 719 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 734 736 732 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 783 788 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 799 801 797 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 818 820 816 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 846 856 844 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vice versa</italic>
###xml 875 879 873 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 899 903 897 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 923 927 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 942 947 940 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
The concomitant occurrence of dhfr, dhps, and crt alleles in identical isolates was analyzed. All dhfr mutations were linked with each other. Dhfr Ile-51 was associated with Asn-108 (OR, 29.8; 95%CI, 8.0-161, P < 0.0001) and Arg-59 (OR, 7.7; 95%CI, 3.3-19,5, P < 0.0001). All isolates exhibiting dhfr Arg-59 additionally had Asn-108 (P < 0.0001). Notably, in isolates with dhfr variant parasites, the CQ-resistance allele crt T76 occurred significantly more frequent than in the respective wildtype isolates (Tab. 1). Separating isolates into such with e.g. dhfr codon 108 pure wildtype, wildtype & mutant, and pure mutant, the prevalence of crt T76 was 67.5% (23/35), 82.4% (14/17), and 86.5% (64/74), respectively (chi2trend = 6.1; P = 0.01). Basically the same trend was seen for dhfr codons 51 (P = 0.002) and 59 (P = 0.002, data not shown). Vice versa, in isolates with crt wildtype, with both crt wildtype & T76, and crt T76 alone, the dhfr triple mutation was detected in 16% (4/25), 53% (9/17), and 55% (46/84), respectively.
###end p 23
###begin p 24
###xml 60 68 <span type="species:ncbi:9606">children</span>
Associations between dhfr and crt mutations in 126 Ghanaian children with uncomplicated malaria
###end p 24
###begin p 25
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr</italic>
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 433 435 433 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
dhfr, dihydrofolate reductase gene, crt, chloroquine resistance transporter gene; 95%CI, 95% confidence interval; CQ, chloroquine; *, Potential confounders were tested for in logistic regression models including age, sex, parasite density, dhps alleles, and axillary temperature. Adjusted odds ratios include the presence of chloroquine in blood as the only factor found to be associated (univariate odds ratio, 3.2; 95%CI, 1.2-8.6; P = 0.01).
###end p 25
###begin p 26
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 263 264 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 264 270 262 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 278 280 276 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 332 337 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 419 423 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 433 434 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 437 442 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhps </italic>
###xml 474 479 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 496 500 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
The prevalence of crt T76 increased with increasing number of any dhfr mutations: it was 63% (20/32) in isolates with pure dhfr wildtype, 74% (26/35) in isolates with single or double mutations, and 93% (55/59) in isolates exhibiting the dhfr triple mutation (chi2trend = 13.1; P = 0.0003). Adjusting for CQ in blood, isolates with dhfr triple mutations revealed a seven-fold increased odds of concomitantly exhibiting crt T76 (Tab. 1). Dhps alleles neither correlated with dhfr alleles nor with crt T76 (data not shown).
###end p 26
###begin p 27
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhfr</italic>
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps</italic>
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 376 381 376 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 536 537 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 537 543 535 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 550 552 548 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 746 751 743 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 771 775 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 848 849 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 852 857 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhfr </italic>
###xml 868 872 865 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 116 124 <span type="species:ncbi:9606">children</span>
Dhfr, dhps, and crt alleles were examined with respect to pre-treatment gametocytaemia. As reported elsewhere [16], children were significantly more likely to harbour gametocytes in the presence of dhfr 51, 59, or triple mutations. This was also true for isolates exhibiting crt T76 (Tab. 2). Gametocytes were not observed in any (0/21) isolate with wildtype alleles for both dhfr and crt, but in 16% (8/50) of isolates exhibiting either dhfr or crt mutations, and in 29% (16/55) of isolates revealing both, dhfr triple and crt T76 (chi2trend = 8.7, P = 0.003). Adjusting for additional factors influencing gametocytaemia, i.e. high parasite density arbitrarily set as >50,000/muL, the presence of CQ in blood, and axillary temperature, both the dhfr triple mutation and crt T76 were associated with an increased likelihood of gametocytaemia (Tab. 2). Dhfr alleles or crt T76 were not associated with gametocyte density (data not shown).
###end p 27
###begin p 28
###xml 62 70 <span type="species:ncbi:9606">children</span>
Associations with pre-treatment gametocytemia in 126 Ghanaian children with uncomplicated malaria
###end p 28
###begin p 29
Ax., axillary; n.a., not applicable
###end p 29
###begin p 30
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 376 378 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 75 83 <span type="species:ncbi:9606">children</span>
###xml 219 227 <span type="species:ncbi:9606">children</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
One week after treatment, gametocytes were observed in 63% (66/104) of the children. Gametocytaemia following SP treatment was associated with pre-treatment dhfr mutations, e.g. dhfr Asn-108, OR 3.1; 95%CI, 1.3-7.6. In children harbouring crt T76 parasites, gametocytes were only slightly more frequent (66% (54/82)) than in patients with crt wildtype parasites (55% (12/22), P = 0.3).
###end p 30
###begin p 31
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 142 150 <span type="species:ncbi:9606">children</span>
Finally, selection of crt T76 in SP treatment failures was examined. No selection was observed: In matched pairs of isolates obtained from 35 children suffering SP treatment failure, crt T76 was present in 86% (30/35) of pre-treatment isolates and in 80% (28/35) of isolates obtained at treatment failure.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 17 31 17 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 17 30 <span type="species:ncbi:5833">P. falciparum</span>
In this study on P. falciparum isolates from northern Ghana, two major findings are presented. First, SP and CQ resistance markers are strongly associated with each other, independent of residual antimalarials. Second, both are associated with an increased prevalence of gametocytes.
###end p 33
###begin p 34
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 873 878 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 891 902 891 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vice versa </italic>
This study has several limitations and particularly the finding of an association between unrelated mutations needs caution in interpretation. Because polyclonal infections predominate in the area [24], the detection of a mutant allele in an isolate does not necessarily mean that all clones carry the mutation. Thus, it cannot be stated whether the linkage between the resistance markers is a true one, i.e. on the chromosomal level, or reflects co-occurrence in individual isolates. The limited number of crt wildtypes also hampered proper testing of a linkage disequilibrium. Although dhfr mutations were significantly more common in the presence of crt T76 this observation needs to be construed with caution since 80% of the isolates in this study harboured the latter variant. Also, it is impossible to comment whether the presence of crt T76 favours the presence of dhfr mutations or vice versa because this requires longitudinal observations. Likewise, the lack of temporal information impairs a clear statement on whether resistance mutations bring about increased gametocytogenesis. Due to methodology the resistance genotype of asexual parasites cannot be separated from that of gametocytes.
###end p 34
###begin p 35
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 568 577 568 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 657 671 657 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 938 942 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1191 1192 1191 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1193 1195 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1881 1883 1881 1883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2032 2036 2032 2036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 2044 2049 2044 2049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 2193 2202 2193 2202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2468 2475 2468 2475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 2573 2575 2573 2575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2637 2646 2637 2646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2716 2718 2716 2718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 2759 2763 2759 2763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 2822 2827 2822 2827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 415 421 <span type="species:ncbi:10090">murine</span>
###xml 657 670 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1613 1621 <span type="species:ncbi:9606">children</span>
Despite these difficulties in drawing firm conclusions, several previous findings support the hypothesis of a linkage disequilibrium between mutations associated with SP resistance and CQ resistance. Early reports from the 1950s and 1960s indicated that in areas or patients with established pyrimethamine-resistance in Nigeria, Burkina Faso, and Venezuela, CQ exhibited a reduced activity (reviewed in [25]). In a murine malaria model, CQ resistance could be induced in pyrimethamine-resistant parasites but not in sensitive ones [11]. In isolates from Cameroon, the in vitro activity of pyrimethamine was ten times lower in CQ resistant than in sensitive P. falciparum [13]. Similar but less pronounced differences have also been observed in other studies [26,27]. In southern Ghana, we previously observed that the dhfr core mutation Asn-108 was three times more likely found in isolates exhibiting crt T76 than in isolates comprising crt wildtype parasites [7]. The reason for this apparent association between resistance to CQ and pyrimethamine or SP is obscure since both drugs have distinct modes of action and resistance to these is determined by mutations on different chromosomes [8-10]. One alluringly simple explanation could be that parasites in the study area have merely become resistant to both drugs, possibly as a result of drug pressure. In this regard, previous, simultaneous or sequential treatment with CQ and SP could have selected for resistant parasites which subsequently persisted for a longer period than the drugs can be detected in blood. However, pyrimethamine was seen in only two children which indicates that it is rarely used in this community and which argues against drug-induced selection for SP resistance. In addition, the results are corrected for the presence of CQ in blood which can be detected for approximately one month after intake [28]. This does not exclude the possibility of selected and persisting parasites but renders it rather unlikely. Alternatively, the association between crt T76 and dhfr mutations could reflect a rapid mutator phenotype with the ability of accelerated resistance to multiple drugs. This hypothesis originates from in vitro studies observing that parasites resistant to common antimalarials acquire resistance to structurally unrelated drugs more rapidly than susceptible strains. The genetic basis of this phenomenon is unknown but suggested to involve an increased frequency of mutations per se and consequently a higher probability of modified proteins which could also include drug targets [12]. In fact, selection for high-grade pyrimethamine resistance in vitro has been shown to enhance the degree of overall genomic polymorphism [29]. In this regard, it is noteworthy that crt T76 was more frequently observed with increasing number of dhfr mutations, i.e. with increasing degree of SP resistance.
###end p 35
###begin p 36
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 717 724 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 760 764 760 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 900 904 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 989 993 989 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1071 1075 1071 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1134 1138 1134 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1200 1204 1200 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1287 1291 1287 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1362 1366 1362 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1381 1383 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1484 1488 1484 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 1492 1497 1492 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 1678 1680 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1887 1891 1887 1891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 2041 2045 2041 2045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt </italic>
###xml 493 501 <span type="species:ncbi:9606">children</span>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
###xml 882 890 <span type="species:ncbi:9606">patients</span>
###xml 2011 2019 <span type="species:ncbi:9606">children</span>
In the present study, the association between the resistance markers meets with an increased presence of gametocytes in isolates comprising mutant dhfr or crt alleles. Gametocytaemia seemed to reflect a rather long duration of infection as can be deduced from its low prevalence in the presence of factors suggestive for acute disease, i.e. high body temperature and parasite density, and previous CQ treatment (Tab. 2). Again, an increased frequency of resistance mutations in gametocytaemic children could result from previous drug-related selection as outlined above. However, increased gametocytaemia preceding treatment has also been observed in infections subsequently found to be CQ resistant [30-32]. Hallett et al. [15] reported that in patients with crt T76 parasites, gametocyte density was highly increased one week following CQ treatment. In addition, gametocytes from patients carrying crt T76 parasites produced 38 times higher oocyst burdens in the mosquito as compared to crt wildtype parasites. In Tamale, both residual CQ levels and parasites with the crt T76 mutation are abundant [33], and a clear association of crt T76 and pre-treatment gametocyte prevalence is seen. Only one crt wildtype isolate contained gametocytes impairing a sound analysis of the effect of crt T76 on gametocyte density. However, increased gametocyte production by crt T76 parasites [15] in the presence of residual CQ could partially explain the present finding. The synthesis of both, crt and dhfr mutations being associated and increased gametocytaemia in their presence, gives rise to a grim scenario: Given that CQ resistant parasites have an improved transmission potential [15] the association with SP resistance would contribute to an accelerating spread of resistance to both drugs, particularly in areas where CQ resistance is frequent. In the present study, neither selection of crt T76 in SP treatment failure was observed nor a significantly elevated proportion of post-treatment gametocytaemia among children initially harbouring crt T76 parasites. Although this was not expected and would reflect an extraordinary rapid process, both observations may be influenced by the small sample size.
###end p 36
###begin title 37
Conclusion
###end title 37
###begin p 38
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Per se</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
The present data provide evidence supporting a hypothesis on a connection between resistance to CQ and SP suggesting that both, CQ and SP resistance favour transmission. This needs to be verified by carefully designed longitudinal studies in regions of differing levels of drug resistance and endemicity. Per se, antimalarial treatment must be effective, and more effective than CQ and SP, not only to reduce treatment failures but also the transmission of potential co-resistance. Eventually, as this has been shown to counterbalance enhanced transmission of resistant parasites [15] the results strongly support combinatory treatment including artemisinine-derivatives.
###end p 38
###begin title 39
Authors' contributions
###end title 39
###begin p 40
###xml 74 81 <span type="species:ncbi:9606">patient</span>
FPM, JTB, and UB designed the study. RNO, SE and FPM were responsible for patient recruitment, clinical and parasitological examinations, and PCR assays. TAE measured drug concentrations. JTB and RWS did the gametocyte counts. FPM and JTB wrote the paper with major contributions of the other authors.
###end p 40
###begin title 41
Acknowledgements
###end title 41
###begin p 42
###xml 13 21 <span type="species:ncbi:9606">children</span>
We thank the children who participated in this study and their parents as well as the members of the Northern Region Malaria Project (NORMAP). Part of this study was funded by the World Health Organization (EPH/CSR, M50-181-9).
###end p 42
###begin article-title 43
Pricing, distribution, and use of antimalarial drugs
###end article-title 43
###begin article-title 44
Antimalarial drug use among caregivers in Ghana
###end article-title 44
###begin article-title 45
A study of malaria care provider choice in Ghana
###end article-title 45
###begin article-title 46
Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study
###end article-title 46
###begin article-title 47
Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: sulfadoxine-pyrimethamine is not working in Malawi
###end article-title 47
###begin article-title 48
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum pfcrt </italic>
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfmdr1 </italic>
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfdhfr </italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana
###end article-title 48
###begin article-title 49
###xml 53 75 53 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 53 74 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization
###end article-title 49
###begin article-title 50
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
###end article-title 50
###begin article-title 51
###xml 17 31 17 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 17 30 <span type="species:ncbi:5833">P. falciparum</span>
Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
###end article-title 51
###begin article-title 52
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium vinckei: </italic>
###xml 0 18 <span type="species:ncbi:5860">Plasmodium vinckei</span>
Plasmodium vinckei: production of chloroquine-resistant strain
###end article-title 52
###begin article-title 53
###xml 48 69 48 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 48 69 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Variations in frequencies of drug resistance in Plasmodium falciparum
###end article-title 53
###begin article-title 54
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 101 122 101 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 101 122 <span type="species:ncbi:5833">Plasmodium falciparum</span>
In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum
###end article-title 54
###begin article-title 55
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria
###end article-title 55
###begin article-title 56
Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes
###end article-title 56
###begin article-title 57
###xml 0 27 0 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum dhfr </italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum dhfr but not dhps mutations associated with sulfadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana
###end article-title 57
###begin article-title 58
A randomised, placebo-controlled, and double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria
###end article-title 58
###begin article-title 59
Severe falciparum malaria
###end article-title 59
###begin article-title 60
Field evaluation of the use of an ELISA to detect chloroquine and its metabolites in blood, urine and breast-milk
###end article-title 60
###begin article-title 61
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion
###end article-title 61
###begin article-title 62
A molecular marker of chloroquine-resistant falciparum malaria
###end article-title 62
###begin article-title 63
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum multiplicity correlates with anaemia in symptomatic malaria
###end article-title 63
###begin article-title 64
Chemotherapy of Malaria
###end article-title 64
###begin article-title 65
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 69 91 69 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 69 90 <span type="species:ncbi:5833">Plasmodium falciparum</span>
In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon
###end article-title 65
###begin article-title 66
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 74 96 74 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 74 95 <span type="species:ncbi:5833">Plasmodium falciparum</span>
In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs
###end article-title 66
###begin article-title 67
Production of monoclonal antibodies against antimalarial drugs for use in immunoassays
###end article-title 67
###begin article-title 68
###xml 50 72 50 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 50 71 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Genome comparison of progressively drug resistant Plasmodium falciparum lines derived from drug sensitive clone
###end article-title 68
###begin article-title 69
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 42 63 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Risk factors of chloroquine resistance in Plasmodium falciparum malaria
###end article-title 69
###begin article-title 70
###xml 29 37 <span type="species:ncbi:9606">children</span>
Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine
###end article-title 70
###begin article-title 71
###xml 11 33 11 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 11 32 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 51 59 <span type="species:ncbi:9606">children</span>
Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections
###end article-title 71
###begin article-title 72
###xml 80 102 80 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 80 101 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 113 121 <span type="species:ncbi:9606">children</span>
Chloroquine blood concentrations and molecular markers of chloroquine-resistant Plasmodium falciparum in febrile children in northern Ghana
###end article-title 72

